Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol

André Hazout, Philippe Bouchard, David Seifer, P. Aussage, Anne Marie Junca, Paul Cohen-Bacrie

Research output: Contribution to journalArticle

241 Citations (Scopus)

Abstract

To test the hypothesis that the concentration of early follicular phase serum antimüllerian hormone (AMH) or müllerian-inhibiting substance (MIS) is a useful marker of ovarian response and assisted reproductive technology (ART) outcome. Retrospective analysis of day 3 serum samples drawn before treatment. Private ART program. One hundred nine consecutive serum samples from women younger than 42 years of age who were undergoing ovulation induction for IVF. Follicular aspiration for IVF after ovarian stimulation with FSH in a down-regulated cycle using GnRH-a treatment. Correlations between day 3 serum AMH/MIS, E2, FSH, inhibin B levels, and IVF outcome (i.e., number of retrieved mature oocytes, number and quality of embryos obtained, ongoing clinical pregnancy rates). Multivariate regression analysis on categorical data was performed to describe a predictive model of clinical pregnancy outcome. Mean serum AMH/MIS value for clinical pregnancy (n = 38) was 2.4 ng/mL, in comparison to 1.1 ng/mL for those who did not become pregnant (n = 71). No differences were noted in mean values for day 3 FSH, inhibin B, or E2 between groups. Multivariate regression analysis demonstrated that day 3 serum AMH/MIS had the greatest independent contribution in predicting pregnancy outcomes. These data demonstrate a strong association between day 3 serum AMH/MIS level and IVF outcome in women younger than 42 years of age. Higher AMH/MIS concentrations are associated with a greater number of mature oocytes, a greater number of embryos, and ultimately a higher clinical pregnancy rate. Furthermore, AMH/MIS may offer greater prognostic value than other currently available serum markers of ART outcome.

Original languageEnglish (US)
Pages (from-to)1323-1329
Number of pages7
JournalFertility and Sterility
Volume82
Issue number5
DOIs
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Assisted Reproductive Techniques
Follicle Stimulating Hormone
Estradiol
Hormones
Serum
Ovulation Induction
Pregnancy Rate
Pregnancy Outcome
Oocytes
Multivariate Analysis
Embryonic Structures
Regression Analysis
Follicular Phase
inhibin B
Gonadotropin-Releasing Hormone
Biomarkers
Pregnancy
Therapeutics

Keywords

  • IVF outcome
  • prognostic markers
  • Serum AMH/MIS

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. / Hazout, André; Bouchard, Philippe; Seifer, David; Aussage, P.; Junca, Anne Marie; Cohen-Bacrie, Paul.

In: Fertility and Sterility, Vol. 82, No. 5, 11.2004, p. 1323-1329.

Research output: Contribution to journalArticle

Hazout, André ; Bouchard, Philippe ; Seifer, David ; Aussage, P. ; Junca, Anne Marie ; Cohen-Bacrie, Paul. / Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. In: Fertility and Sterility. 2004 ; Vol. 82, No. 5. pp. 1323-1329.
@article{184a3d9baf2d46c7a2ad5538e7c9f97a,
title = "Serum antim{\"u}llerian hormone/m{\"u}llerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol",
abstract = "To test the hypothesis that the concentration of early follicular phase serum antim{\"u}llerian hormone (AMH) or m{\"u}llerian-inhibiting substance (MIS) is a useful marker of ovarian response and assisted reproductive technology (ART) outcome. Retrospective analysis of day 3 serum samples drawn before treatment. Private ART program. One hundred nine consecutive serum samples from women younger than 42 years of age who were undergoing ovulation induction for IVF. Follicular aspiration for IVF after ovarian stimulation with FSH in a down-regulated cycle using GnRH-a treatment. Correlations between day 3 serum AMH/MIS, E2, FSH, inhibin B levels, and IVF outcome (i.e., number of retrieved mature oocytes, number and quality of embryos obtained, ongoing clinical pregnancy rates). Multivariate regression analysis on categorical data was performed to describe a predictive model of clinical pregnancy outcome. Mean serum AMH/MIS value for clinical pregnancy (n = 38) was 2.4 ng/mL, in comparison to 1.1 ng/mL for those who did not become pregnant (n = 71). No differences were noted in mean values for day 3 FSH, inhibin B, or E2 between groups. Multivariate regression analysis demonstrated that day 3 serum AMH/MIS had the greatest independent contribution in predicting pregnancy outcomes. These data demonstrate a strong association between day 3 serum AMH/MIS level and IVF outcome in women younger than 42 years of age. Higher AMH/MIS concentrations are associated with a greater number of mature oocytes, a greater number of embryos, and ultimately a higher clinical pregnancy rate. Furthermore, AMH/MIS may offer greater prognostic value than other currently available serum markers of ART outcome.",
keywords = "IVF outcome, prognostic markers, Serum AMH/MIS",
author = "Andr{\'e} Hazout and Philippe Bouchard and David Seifer and P. Aussage and Junca, {Anne Marie} and Paul Cohen-Bacrie",
year = "2004",
month = "11",
doi = "10.1016/j.fertnstert.2004.03.061",
language = "English (US)",
volume = "82",
pages = "1323--1329",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol

AU - Hazout, André

AU - Bouchard, Philippe

AU - Seifer, David

AU - Aussage, P.

AU - Junca, Anne Marie

AU - Cohen-Bacrie, Paul

PY - 2004/11

Y1 - 2004/11

N2 - To test the hypothesis that the concentration of early follicular phase serum antimüllerian hormone (AMH) or müllerian-inhibiting substance (MIS) is a useful marker of ovarian response and assisted reproductive technology (ART) outcome. Retrospective analysis of day 3 serum samples drawn before treatment. Private ART program. One hundred nine consecutive serum samples from women younger than 42 years of age who were undergoing ovulation induction for IVF. Follicular aspiration for IVF after ovarian stimulation with FSH in a down-regulated cycle using GnRH-a treatment. Correlations between day 3 serum AMH/MIS, E2, FSH, inhibin B levels, and IVF outcome (i.e., number of retrieved mature oocytes, number and quality of embryos obtained, ongoing clinical pregnancy rates). Multivariate regression analysis on categorical data was performed to describe a predictive model of clinical pregnancy outcome. Mean serum AMH/MIS value for clinical pregnancy (n = 38) was 2.4 ng/mL, in comparison to 1.1 ng/mL for those who did not become pregnant (n = 71). No differences were noted in mean values for day 3 FSH, inhibin B, or E2 between groups. Multivariate regression analysis demonstrated that day 3 serum AMH/MIS had the greatest independent contribution in predicting pregnancy outcomes. These data demonstrate a strong association between day 3 serum AMH/MIS level and IVF outcome in women younger than 42 years of age. Higher AMH/MIS concentrations are associated with a greater number of mature oocytes, a greater number of embryos, and ultimately a higher clinical pregnancy rate. Furthermore, AMH/MIS may offer greater prognostic value than other currently available serum markers of ART outcome.

AB - To test the hypothesis that the concentration of early follicular phase serum antimüllerian hormone (AMH) or müllerian-inhibiting substance (MIS) is a useful marker of ovarian response and assisted reproductive technology (ART) outcome. Retrospective analysis of day 3 serum samples drawn before treatment. Private ART program. One hundred nine consecutive serum samples from women younger than 42 years of age who were undergoing ovulation induction for IVF. Follicular aspiration for IVF after ovarian stimulation with FSH in a down-regulated cycle using GnRH-a treatment. Correlations between day 3 serum AMH/MIS, E2, FSH, inhibin B levels, and IVF outcome (i.e., number of retrieved mature oocytes, number and quality of embryos obtained, ongoing clinical pregnancy rates). Multivariate regression analysis on categorical data was performed to describe a predictive model of clinical pregnancy outcome. Mean serum AMH/MIS value for clinical pregnancy (n = 38) was 2.4 ng/mL, in comparison to 1.1 ng/mL for those who did not become pregnant (n = 71). No differences were noted in mean values for day 3 FSH, inhibin B, or E2 between groups. Multivariate regression analysis demonstrated that day 3 serum AMH/MIS had the greatest independent contribution in predicting pregnancy outcomes. These data demonstrate a strong association between day 3 serum AMH/MIS level and IVF outcome in women younger than 42 years of age. Higher AMH/MIS concentrations are associated with a greater number of mature oocytes, a greater number of embryos, and ultimately a higher clinical pregnancy rate. Furthermore, AMH/MIS may offer greater prognostic value than other currently available serum markers of ART outcome.

KW - IVF outcome

KW - prognostic markers

KW - Serum AMH/MIS

UR - http://www.scopus.com/inward/record.url?scp=7944232016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944232016&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2004.03.061

DO - 10.1016/j.fertnstert.2004.03.061

M3 - Article

VL - 82

SP - 1323

EP - 1329

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 5

ER -